Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
|Podcasts|August 16, 2022
The Cutaneous Connection: Pediatric Atopic Dermatitis and Shin Guard Dermatitis
Author(s)Kaitlyn Bader, Associate Editor
In this episode, Peter Lio, MD, and clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.
Advertisement
Advertisement
Related to this article
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Improving Early Identification and Escalation of HS
4
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
5